Study of LL-BMT1 in Patients With Elevated Intraocular Pressure

• Status: Completed
• Trial end date: 2021-02-16
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single dose of LL-BMT1.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: MediPrint Ophthalmics, Inc.

Criteria

Inclusion Criteria:

• Male or female, at least 18 years of age at the Screening Visit

• Diagnosed with primary open-angle glaucoma or ocular hypertension in both eyes

• At least one eye (called the study eye) must have an untreated intraocular pressure between 22 mmHg and 34 mmHg (inclusive) as measured at 9 am during the Baseline Visit.

• Best corrected visual acuity of Early Treatment Diabetic Retinopathy Study of 50 letters or better

Exclusion Criteria:

• Glaucoma or optic neuropathy due to anything other than above noted reasons Cup-to-disc ratio of >0.8 in either eye

• Corneal thickness <480 or >620 μm